Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INBRX-109 |
Synonyms | |
Therapy Description |
INBRX-109 is a tetravalent agonistic antibody against DR5 (TNFRSF10B), which may activate the receptor to promote apoptosis (PMID: 37265425). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INBRX-109 | INBRX109|INBRX 109 | INBRX-109 is a tetravalent agonistic antibody against DR5 (TNFRSF10B), which may activate the receptor to promote apoptosis (PMID: 37265425). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | 0 |
NCT04950075 | Phase II | INBRX-109 | Study of INBRX-109 in Conventional Chondrosarcoma | Recruiting | USA | NLD | ITA | IRL | GBR | FRA | ESP | DEU | AUS | 0 |